TNGX vs. DNTH, ARCT, EOLS, ZNTL, LBPH, ALXO, IRON, PRAX, PLRX, and SPRY
Should you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Dianthus Therapeutics (DNTH), Arcturus Therapeutics (ARCT), Evolus (EOLS), Zentalis Pharmaceuticals (ZNTL), Longboard Pharmaceuticals (LBPH), ALX Oncology (ALXO), Disc Medicine (IRON), Praxis Precision Medicines (PRAX), Pliant Therapeutics (PLRX), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical preparations" industry.
Tango Therapeutics (NASDAQ:TNGX) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, community ranking, valuation, media sentiment, institutional ownership, risk, earnings and dividends.
Tango Therapeutics received 2 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Dianthus Therapeutics an outperform vote while only 56.52% of users gave Tango Therapeutics an outperform vote.
Dianthus Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -299.88%. Dianthus Therapeutics' return on equity of -20.82% beat Tango Therapeutics' return on equity.
79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 6.2% of Tango Therapeutics shares are owned by insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Dianthus Therapeutics has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tango Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.
Tango Therapeutics presently has a consensus target price of $17.25, indicating a potential upside of 117.53%. Dianthus Therapeutics has a consensus target price of $42.83, indicating a potential upside of 61.64%. Given Tango Therapeutics' higher probable upside, research analysts plainly believe Tango Therapeutics is more favorable than Dianthus Therapeutics.
In the previous week, Dianthus Therapeutics had 2 more articles in the media than Tango Therapeutics. MarketBeat recorded 15 mentions for Dianthus Therapeutics and 13 mentions for Tango Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.08 beat Tango Therapeutics' score of -0.23 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.
Summary
Dianthus Therapeutics beats Tango Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Tango Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tango Therapeutics Competitors List
Related Companies and Tools
